Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 12/2017

01-12-2017 | Original Article

The relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial calcification and stiffness: a cross-sectional study in post-menopausal women

Authors: N. Tanna, K. Patel, A. E. Moore, D. Dulnoan, S. Edwards, G. Hampson

Published in: Journal of Endocrinological Investigation | Issue 12/2017

Login to get access

Abstract

Objective

To explore the relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial stiffness and vascular calcification in post-menopausal women. We hypothesised that adipokines produced by adipose tissue may be mediators of bone and cardiovascular disease (CVD) and explain, in part, the observed association between osteoporosis and CVD.

Design

We studied 386 ambulant community dwelling postmenopausal women aged (mean [SD] 61 [6.4] years). BMD at the lumbar spine, femoral neck (FN), and total hip (TH), body composition; fat mass (FM) and lean mass (LM) as well as abdominal aortic calcification (AAC) were determined by dual energy X-ray absorptiometry. Pulse wave velocity (PWV) and augmentation index, markers of arterial stiffness were measured. Fasting adiponectin, leptin and vaspin were quantified in serum.

Results

A positive independent association was observed between vaspin and BMD at the FN (p = 0.009), TH (p = 0.037) in the whole study population adjusted for confounders including age, FM, LM and lifestyle variables. Using the same model, a negative association was seen between adiponectin and BMD at the FN in women with osteoporosis (p = 0.043). Serum adiponectin was significantly higher in women with fractures (20.8 [9.3] µg/ml compared to those without (18.5 [8.6] µg/ml, p = 0.018) and associated with a significant increased risk of fracture (HR 1.032, 95% CI 1.003–1.063, p = 0.032). Leptin was not associated with BMD or fracture risk after adjustment. Adiponectin was independently associated with AAC (p = 0.007) and significantly higher in women with AAC scores > 1; (19.2[9.2]) compared to those with no or low AAC scores (<1); 16.8 [8.0], p = 0.018). In adjusted analyses, PWV velocity was positively associated with circulating vaspin (p = 0.039) and AI was negatively associated with serum leptin (p = 0.002).

Conclusion

Adiponectin, leptin, vaspin are related to markers of bone and vascular health and may contribute to the observed association between osteoporosis and CVD.
Literature
1.
Lampropoulos CE, Papaioannou I, D’Cruz DP (2012) Osteoporosis–a risk factor for cardiovascular disease? Nat Rev Rheumatol 8(10):587–598CrossRefPubMed
2.
von der Recke P, Hansen MA, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106(3):273–278CrossRefPubMed
3.
Buckens CF, de Jong PA, Verkooijen HM, Verhaar HJ, Mali WP, van der Graaf Y et al (2015) Vertebral fractures on routine chest computed tomography: relation with arterial calcifications and future cardiovascular events. Int J Cardiovasc Imaging 31(2):437–445CrossRefPubMed
4.
Vassalle C, Mazzone A (2016) Bone loss and vascular calcification: A bi-directional interplay? Vascul Pharmacol 86:77–86CrossRefPubMed
5.
Evenepoel P, D’Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235–240CrossRefPubMed
6.
7.
Armstrong ME, Cairns BJ, Banks E, Green J, Reeves GK, Beral V et al (2012) Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone 50(6):1394–1400CrossRefPubMedPubMedCentral
8.
Premaor MO, Pilbrow L, Tonkin C, Parker RA, Compston J (2010) Obesity and fractures in postmenopausal women. J Bone Miner Res 25(2):292–297CrossRefPubMed
9.
Ebong IA, Goff DC Jr, Rodriguez CJ, Chen H, Bluemke DA, Szklo M et al (2013) The relationship between measures of obesity and incident heart failure: the multi-ethnic study of atherosclerosis. Obesity (Silver Spring) 21(9):1915–1922
10.
Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, Vita JA et al (2007) Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation 115(20):2628–2636CrossRefPubMed
11.
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548–2556CrossRefPubMed
12.
Pepe J, Cipriani C, Cilli M, Colangelo L, Minisola S (2016) Adipokines and bone metabolism: an interplay to untangle. J Endocrinol Invest 39(11):1359–1361CrossRefPubMed
13.
Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I et al (2011) Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 96(9):2703–2713CrossRefPubMed
14.
Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92(4):1517–1523CrossRefPubMed
15.
Napoli N, Pedone C, Pozzilli P, Lauretani F, Ferrucci L, Incalzi RA (2010) Adiponectin and bone mass density: the InCHIANTI study. Bone 47(6):1001–1005CrossRefPubMedPubMedCentral
16.
Liu Y, Song CY, Wu SS, Liang QH, Yuan LQ, Liao EY (2013) Novel adipokines and bone metabolism. Int J Endocrinol 2013:895045PubMedPubMedCentral
17.
Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B et al (2013) Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab 17(6):901–915CrossRefPubMedPubMedCentral
18.
Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J et al (2005) Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331(2):520–526CrossRefPubMed
19.
Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB et al (2009) In vitro and in vivo effects of adiponectin on bone. Endocrinology 150(8):3603–3610CrossRefPubMed
20.
Zhu X, Jiang Y, Shan PF, Shen J, Liang QH, Cui RR et al (2013) Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids 44(3):961–968CrossRefPubMed
21.
Kamio N, Kawato T, Tanabe N, Kitami S, Morita T, Ochiai K et al (2013) Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. Connect Tissue Res 54(2):147–152CrossRefPubMed
22.
Mattu HS, Randeva HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216(1):T17–T36CrossRefPubMed
23.
Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y et al (2009) Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 46(3):413–419CrossRefPubMed
24.
Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D et al (2005) Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111(6):747–753CrossRefPubMed
25.
Johansen NB, Vistisen D, Brunner EJ, Tabak AG, Shipley MJ, Wilkinson IB et al (2012) Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study. PLoS ONE 7(5):e37165CrossRefPubMedPubMedCentral
26.
Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB et al (2008) Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 93(4):1489–1496CrossRefPubMed
27.
Zachariah JP, Hwang S, Hamburg NM, Benjamin EJ, Larson MG, Levy D et al (2016) Circulating adipokines and vascular function: cross-sectional associations in a community-based cohort. Hypertension 67(2):294–300PubMed
28.
Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K et al (1999) Leptin is associated with increased risk of myocardial infarction. J Intern Med 246(4):409–418CrossRefPubMed
29.
Sawicka M, Janowska J, Chudek J (2016) Potential beneficial effect of some adipokines positively correlated with the adipose tissue content on the cardiovascular system. Int J Cardiol 222:581–589CrossRefPubMed
30.
Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56(1):42–47CrossRefPubMed
31.
Spangenberg A, Maghsoodi N, Dulnoan D, Moore AE, Edwards S, Frost ML et al (2016) Bone mineral density and body composition are associated with circulating angiogenic factors in post-menopausal women. Calcif Tissue Int 99(6):608–615CrossRefPubMedPubMedCentral
32.
Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55(13):1318–1327CrossRefPubMed
33.
Tomiyama H, Yamashina A (2010) Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 74(1):24–33CrossRefPubMed
34.
Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE (2016) Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 28(7):814–819CrossRefPubMed
35.
Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A et al (2011) Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS ONE 6(9):e24240CrossRefPubMedPubMedCentral
36.
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A et al (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102(30):10610–10615CrossRefPubMedPubMedCentral
37.
38.
39.
Mpalaris V, Anagnostis P, Anastasilakis AD, Goulis DG, Doumas A, Iakovou I (2016) Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: Is there an association with bone mineral density? Maturitas 88:32–36CrossRefPubMed
40.
Johansson H, Oden A, Lerner UH, Jutberger H, Lorentzon M, Barrett-Connor E et al (2012) High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res 27(6):1390–1396CrossRefPubMed
41.
Araneta MR, von Muhlen D, Barrett-Connor E (2009) Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone Miner Res 24(12):2016–2022CrossRefPubMedPubMedCentral
42.
Modder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG et al (2011) Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 49(2):202–207CrossRefPubMedPubMedCentral
43.
Steffes MW, Gross MD, Lee DH, Schreiner PJ, Jacobs DR Jr (2006) Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the Coronary Artery Risk Development in Young Adults Study. Obesity (Silver Spring) 14(2):319–326CrossRef
44.
Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ et al (2011) Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf) 75(5):628–635CrossRef
45.
Karbek B, Bozkurt NC, Topaloglu O, Aslan MS, Gungunes A, Cakal E et al (2014) Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome. Minerva Endocrinol 39(2):99–105PubMed
46.
Dimova R, Tankova T (2015) The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. Biomed Res Int 2015:823481CrossRefPubMedPubMedCentral
47.
Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K (2003) Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 26(2):147–152CrossRefPubMed
48.
Garonna E, Botham KM, Birdsey GM, Randi AM, Gonzalez-Perez RR, Wheeler-Jones CP (2011) Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS ONE 6(4):e18823CrossRefPubMedPubMedCentral
49.
Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L et al (2011) Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 58(2):186–192CrossRefPubMedPubMedCentral
Metadata
Title
The relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial calcification and stiffness: a cross-sectional study in post-menopausal women
Authors
N. Tanna
K. Patel
A. E. Moore
D. Dulnoan
S. Edwards
G. Hampson
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 12/2017
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-017-0711-1

Other articles of this Issue 12/2017

Journal of Endocrinological Investigation 12/2017 Go to the issue

Consensus Statement

The use of nutraceuticals in male sexual and reproductive disturbances: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS)

Original Article

Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic

Original Article

Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy

Original Article

Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome

Original Article

Correlation of cardio-metabolic parameters with vitamin D status in healthy premenopausal women

Original Article

The relationship between hyperthyrotropinemia and metabolic and cardiovascular risk factors in a large group of overweight and obese children and adolescents
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits